(Q24240125)

19 October 2023

5

Andrea Cipriani

Andrea

Cipriani

1 reference

19 October 2023

7

Rachel Churchill

Rachel

Churchill

1 reference

19 October 2023

Atsuo Nakagawa

1

Atsuo

Nakagawa

1 reference

19 October 2023

6

Hugh McGuire

Hugh

McGuire

1 reference

19 October 2023

8

Toshi A Furukawa

Toshi A

Furukawa

1 reference

19 October 2023

3

Ichiro M Omori

Ichiro M

Omori

1 reference

19 October 2023

2

Norio Watanabe

Norio

Watanabe

1 reference

19588396

Cochrane Database of Systematic Reviews

19 October 2023

language of work or name

English

0 references

publication date

2009

0 references

published in

0 references

issue

3

0 references

page(s)

CD006529

0 references

cites work

Mirtazapine versus other antidepressive agents for depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Fluvoxamine versus other anti-depressive agents for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Escitalopram versus other antidepressive agents for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Fluoxetine versus other types of pharmacotherapy for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

A rating scale for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Sertraline versus other antidepressive agents for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

St John's wort for major depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Amitriptyline versus other types of pharmacotherapy for depression

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Measuring inconsistency in meta-analyses

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Milnacipran and selective serotonin reuptake inhibitors in major depression

19 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

19 March 2017

https://api.crossref.org/works/10.1002%2F14651858.CD006529.PUB2

Preclinical pharmacology of milnacipran

21 January 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

19 March 2017

https://api.crossref.org/works/10.1002%2F14651858.CD006529.PUB2

Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Imputing missing standard deviations in meta-analyses can provide accurate results

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Combination of direct and indirect evidence in mixed treatment comparisons

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

The global burden of typhoid fever

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Scope and impact of financial conflicts of interest in biomedical research: a systematic review

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Detecting skewness from summary information

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

A New Depression Scale Designed to be Sensitive to Change

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Evaluation of networks of randomized trials

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Duloxetine: a review of its use in the treatment of major depressive disorder

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Challenges in systematic reviews that evaluate drug efficacy or effectiveness

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

The economic burden of depression in the US: societal and patient perspectives

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

A comparative study of milnacipran and paroxetine in outpatients with major depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Are we going to increase the use of antidepressants up to that of benzodiazepines?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Australian and New Zealand clinical practice guidelines for the treatment of depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

"Wish bias" in antidepressant drug trials?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Industry sponsorship and authorship of clinical trials over 20 years

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

The economic burden of depression in the United States: how did it change between 1990 and 2000?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Placebo response in studies of major depression: variable, substantial, and growing

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Standardizing the Hamilton Depression Rating Scale: past, present, and future

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

SSRIs versus other antidepressants for depressive disorder

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

A systematic review of newer pharmacotherapies for depression in adults: evidence report summary

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Milnacipran. A review of its use in depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

A consumer's guide to subgroup analyses

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Clinical efficacy of milnacipran: placebo-controlled trials.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Pharmacokinetics of milnacipran in comparison with other antidepressants

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Pooling two controlled comparisons of milnacipran (F2207) and amitriptyline in endogenous inpatients. A new approach in dose ranging studies

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients

30 May 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529.PUB2

Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529.PUB2

A comparative study of milnacipran and imipramine in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529.PUB2

Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529.PUB2

Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529.PUB2

A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529.PUB2

Controlled comparison of two different doses of milnacipran in major depressive outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529.PUB2

Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529.PUB2

Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529.PUB2

Prevalence, nature, and comorbidity of depressive disorders in primary care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529.PUB2

Citalopram versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529.PUB2

Indirect comparisons: the mesh and mess of clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529.PUB2

Placebo in clinical trials for depression: complexity and necessity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529.PUB2

Clinician's judgments of mental health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529.PUB2

Duloxetine versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529.PUB2

Fluvoxamine versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529.PUB2

Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529.PUB2

Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529.PUB2

Imputing response rates from means and standard deviations in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529.PUB2

The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006529.PUB2

Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

Pharmacokinetics and drug interactions of antidepressive agents

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

A double-blind six months comparative study of milnacipran and clomipramine in major depressive disorder.

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4164845

[Clinico-economic assessment of milnacipran in the prevention of depressive episodes]

29 November 2018

1 reference

12 December 2020

Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association

1 reference

12 December 2020

Prevention of recurrent depressive episodes with milnacipran: consequences on quality of life

1 reference

12 December 2020

Milnacipran efficacy in the prevention of recurrent depression: a 12-month placebo-controlled study. Milnacipran recurrence prevention study group

1 reference

12 December 2020

Network meta-analysis for indirect treatment comparisons

1 reference

12 December 2020

Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports

1 reference

12 December 2020

Economic assessment of a maintenance treatment strategy in prevention of recurrent depressive disorder

1 reference

12 December 2020

Remission rates with milnacipran 100 mg/day and 150 mg/day in the long-term treatment of major depression

1 reference

12 December 2020

Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders

1 reference

12 December 2020

Controlled comparison of milnacipran and fluoxetine in major depression

1 reference

12 December 2020

Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode

1 reference

12 December 2020

A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients

1 reference

12 December 2020

10.1002/14651858.CD006529.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_iopzyl4caze5bpjpo5cnqifsti

0 references

PMC publication ID

4164845

0 references